MTOR and hyperlipidemia: In context with hyperglycemia and hyperlipidemia, the rapamycin pathway is associated with insulin signaling, and mTOR inhibitors are likely to cause insulin resistance and prevent lipid clearance from blood, which results in high lipid and glucose levels.